CLINICAL TRIALS PROFILE FOR TRILEPTAL

All Clinical Trials for TRILEPTAL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00050934 ↗	Pediatric Epilepsy Study	Completed	Novartis Pharmaceuticals	Phase 3	2002-06-01	This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00050947 ↗	Pediatric Epilepsy Study	Completed	Novartis Pharmaceuticals	Phase 3	2002-07-01	This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00108056 ↗	Enzastaurin to Treat Recurrent Brain Tumor	Terminated	National Cancer Institute (NCI)	Phase 1	2005-04-07	This study will examine the safety of a twice-a-day dosing regimen of the experimental drug Enzastaurin in patients with malignant glioma (a cancerous brain tumor) who are and who are not taking certain anti-seizure medicines. Enzastaurin may prevent the formation of new blood vessels that tumors need to grow. It has shown some effect against brain tumors in animals and in some patients with recurrent gliomas. This study will see if the drug can help patients with gliomas and how much drug they should be given. Patients 18 years of age and older with malignant glioma that has recurred after standard therapy may be eligible for this study. Candidates are screened with a physical examination, blood and urine tests, magnetic resonance imaging (MRI) or computed tomography (CT) scans, and an electrocardiogram. Participants are divided into two groups of patients-those who are and those who are not taking certain anti-seizure medications-in order to determine if the anti-seizure medication alters the way the body handles Enzastaurin. Patients in both groups are further divided into different dosing regimens: some in each group take Enzastaurin once a day for 3 weeks, followed by twice a day for 3 weeks; others in the group take the drug twice a day for 3 weeks followed by once a day for 3 weeks. The medication is taken by mouth every day. Treatment is given in 6-week cycles and may continue for 1 year unless the tumor grows or the patient develops unacceptable drug side effects. In addition to drug treatment, patients have the following tests and procedures: - Medical history, physical, and neurological examinations every 3 weeks during the first cycle and then every 6 weeks. - MRI or CT scan of the head before starting each new cycle. MRI uses a magnetic field and radio waves to produce images of body tissues and organs. CT uses x-rays to provide 3-dimensional views of the part of the body being studied. For both procedures, the patient lies on a table that slides into the cylindrical scanner. - Routine blood tests every week during the first cycle and every 3 weeks after that. - Electrocardiogram on days 21 and 42 of the first cycle, just before taking the drug and 30 minutes and 4 hours after taking the drug. - Pharmacokinetic studies within 3 days of day 21 of the first cycle. Several blood samples are drawn to measure levels of Enzastaurin. Patients taking the drug once a day have blood samples drawn before the morning dose and 1, 2, 4, 6 and 24 hours after the dose. Patients taking the drug twice a day have samples drawn before the morning dose, at 1, 2, 4, 6 and 12 hours after the dose, and then 12 hours after the evening dose. In addition, on day 1 an extra tube of blood is drawn at the time of the Enzastaurin dose and 4 hours later. - Dynamic MRI with spectroscopy or PET. These tests are done to help distinguish live tumor from dying tumor. The experience of dynamic MRI with spectroscopy is the same as standard MRI and is done at the same time as the standard procedure. PET uses a radioactive substance to show cellular activity in specific tissues of the body. The patient is given an injection of a sugar solution in which a radioactive isotope has been attached to the sugar molecule. A special camera detects the radiation emitted by the radioisotope, and the resulting images show how much glucose is being used in various parts of the body. Because rapidly growing cells, such as tumors, take up and use more glucose than normal cells do, this test can be used to show active tumors.
NCT00206778 ↗	Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania	Completed	Beth Israel Medical Center	Phase 2	2003-07-01	We are comparing the efficacy of Lamotrigine to that of Standard of Care Sodium Valproate for the treatment of Mixed Mania. The study hypothesis is that Lamotrigine will be more efficative for treating mixed mania in patients with Bipolar Disorder.

Clinical Trial Conditions for TRILEPTAL

Condition Name

Condition Name for TRILEPTAL
Intervention	Trials
Epilepsy	6
Seizures	5
Healthy	4
Epilepsy, Partial	1

Condition MeSH

Condition MeSH for TRILEPTAL
Intervention	Trials
Epilepsy	6
Seizures	5
Bipolar Disorder	3
Epilepsies, Partial	3

Clinical Trial Locations for TRILEPTAL

Trials by Country

Trials by Country for TRILEPTAL
Location	Trials
United States	55
Canada	4
Mexico	2
Germany	2
Brazil	2

Trials by US State

Trials by US State for TRILEPTAL
Location	Trials
New York	5
Texas	4
Pennsylvania	4
Missouri	4
Massachusetts	3

Clinical Trial Progress for TRILEPTAL

Clinical Trial Phase

Clinical Trial Phase for TRILEPTAL
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	3
Phase 2	2

Clinical Trial Status

Clinical Trial Status for TRILEPTAL
Clinical Trial Phase	Trials
Completed	19
Unknown status	2
Terminated	2

Clinical Trial Sponsors for TRILEPTAL

Sponsor Name

Sponsor Name for TRILEPTAL
Sponsor	Trials
Roxane Laboratories	5
Novartis Pharmaceuticals	3
Bial - Portela C S.A.	2

Sponsor Type

Sponsor Type for TRILEPTAL
Sponsor	Trials
Other	31
Industry	14
NIH	1

Last updated: May 3, 2026

Trileptal (oxcarbazepine): Clinical Trial Update, Market Analysis and Forward Projection

Trileptal’s current value proposition sits on long-established use in epilepsy and the treatment of trigeminal neuralgia, with demand supported by routine generic penetration. Clinical trial activity continues, but incremental regulatory and label expansion is not visible at scale in the public record, so commercial upside is tied primarily to prevailing diagnosis rates, competitive dynamics in generics, and regional reimbursement.

What is Trileptal’s clinical status and trial activity now?

Trileptal is the brand of oxcarbazepine, an antiepileptic drug used for:

• Focal (partial-onset) seizures in patients with epilepsy
• Adjunctive therapy in certain pediatric and adult populations
• Trigeminal neuralgia

Publicly accessible clinical-trial records show ongoing studies, largely in these categories:

• Phase 1 to 3 studies for formulation, tolerability, and dosing strategies
• Special populations and comparative effectiveness studies (including switching and real-world follow-up)
• Long-term safety work that typically supports label maintenance rather than major new indications

Clinical update (high-level):

• Active trial listings persist, but the footprint is dominated by trials that do not represent a new major MOA discovery cycle.
• Commercial impact from these trials is therefore indirect: they support continuity of evidence and safety monitoring rather than a step-change in prescribing.

Key implication for investors and BD:

• Patent-driven re-positioning risk is low because the molecule is mature and the market is already generic-led.
• Trial activity is more consistent with lifecycle management than a pathway to premium pricing.

---

What is Trileptal’s market position by demand drivers and competitive structure?

Demand drivers

Trileptal’s demand is driven by:

1. Epilepsy prevalence and treatment adherence in major markets
2. Clinician familiarity with oxcarbazepine-based regimens for focal seizures
3. Chronic use durability (patients typically stay on therapy if tolerated)
4. Trigeminal neuralgia treatment continuity in markets where oxcarbazepine is included in local practice pathways

Competitive structure

Trileptal faces a generic-dominant competitive landscape:

• Brand pricing is typically pressured by multiple generic equivalents in many jurisdictions.
• In practice, formularies often prefer low-cost alternatives unless the brand has a specific formulary listing advantage or a patient-need justification.

Commercial consequence:

• Market growth is usually tied to incremental patient volume rather than price expansion.
• Growth dispersion increases across countries based on reimbursement and formulary controls.

---

How will the market likely evolve over the next 5 years?

Below is a projection framework built for a mature, generic-competing antiepileptic product where growth is driven by patient starts, adherence, and geography-specific reimbursement rather than brand-led label expansion.

Projection logic (generic-era dynamics)

For oxcarbazepine brands, typical drivers of change are:

• Volume trend: diagnosis and treatment rates (epilepsy incidence and prevalence)
• Switching and substitution: generic price differentials and formulary tiering
• Real-world persistence: tolerability-driven discontinuation rates
• Regional policy: price controls, tendering, and reimbursement criteria

Base case (most likely)

• Modest volume growth in major epilepsy markets.
• Ongoing erosion in share where generic substitution tightens.
• Brand volumes may remain stable where prescribers prefer oxcarbazepine products and where switching barriers exist (e.g., stability on therapy, patient-specific reasons).

Bull case

• Faster-than-expected persistence improvements due to better tolerability profiles and guideline alignment.
• Continued steady use in trigeminal neuralgia cohorts in regions with supportive prescribing pathways.
• Brand retention in select formularies that preserve some premium tiering.

Bear case

• Intensified tendering and steeper generic price pressure.
• Greater substitution within the same drug class due to payer-driven step therapy.
• Slower uptake in certain geographies tied to cost-containment measures.

---

What are the key investment and R&D signals to track for Trileptal?

Clinical signals

• Evidence of new dosing regimens that improve tolerability or reduce discontinuation.
• Trials that support broader pediatric or specific epilepsy phenotypes through subgroup analyses.
• Long-term safety studies that reduce monitoring friction with payers and clinicians.

Market signals

• Formulary moves: brand positioning vs generics (tier placement, prior authorization).
• Pricing and tender activity by major government buyers.
• Shifts in market share within antiepileptic drug classes (focal seizure therapies).

Risk signals

• Generic supply changes that can swing pricing.
• Competitor uptake within first-line focal seizure management.
• Payer policy changes that tighten substitution or require step therapy.

---

What does “clinical trial update” look like in practical terms for a mature drug?

For mature antiepileptics like oxcarbazepine, “clinical trial update” usually means:

• No breakthrough clinical differentiation
• Evidence refresh for labeling, safety, and practical dosing
• Data that clinicians can use for real-world decision-making (tolerability, switching, adherence support)

This profile typically supports stable access but does not usually re-price the product meaningfully above generic baselines.

---

Market projection table (scenario-based, directionally stated)

Scenario	Volume (market demand)	Price/Net revenue (brand vs generics)	Share dynamics	Likely outcome
Base case	Low single-digit growth	Downward pressure or flat net pricing	Gradual substitution	Stable brand revenue profile, limited upside
Bull case	Mid single-digit growth	Softer pricing pressure in select regions	Brand holds tiering longer	Better-than-base revenue retention
Bear case	Flat to low growth	Stronger generic price compression	Faster substitution	Revenue declines or sharp share loss

---

Key Takeaways

• Trileptal’s clinical program is consistent with lifecycle management rather than a new major indication or premium pricing catalyst.
• The market is generic-dominant, so future commercial performance depends on volume trends, formulary placement, and regional reimbursement, not brand-led innovation.
• Near-to-mid term upside is most sensitive to persistence, tolerability-driven adherence, and payer tiering.
• The main risk remains accelerated generic substitution driven by tenders and cost-containment.

---

FAQs

1) Is Trileptal’s clinical development focused on new indications?

Clinical trial activity appears oriented toward evidence maintenance and practical dosing/tolerability work, which generally supports existing uses rather than a new high-impact indication.

2) What matters most commercially for Trileptal in the next 5 years?

Formulary tiering, substitution behavior versus generics, tender pricing, and regional reimbursement rules will determine brand-level net revenue more than trial headline results.

3) Does new clinical evidence usually change prescribing volume for Trileptal?

It can improve clinician confidence and adherence, but for mature and genericized products the effect is typically incremental rather than transformational.

4) What is the main competitive pressure for Trileptal?

Multiple generic competitors for oxcarbazepine compress brand pricing and shift share based on payer cost controls and substitution policies.

5) Where could market performance differ most across geographies?

Regions with tighter tendering and restrictive formulary rules will see faster substitution, while markets with broader access and more stable prescribing patterns may show stronger volume retention.

---

References

[1] ClinicalTrials.gov. “Trileptal (oxcarbazepine) clinical studies.” U.S. National Library of Medicine. https://clinicaltrials.gov/
[2] FDA. “Trileptal (oxcarbazepine) Prescribing Information.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
[3] EMA. “Trileptal (oxcarbazepine) EPAR and product information.” European Medicines Agency. https://www.ema.europa.eu/